Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 13/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | METAP2 | P50579 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6813767 | 0.82 | MMP13 (0.39) | — | |
| SCHEMBL6912473 | 0.74 | MMP13 (0.38) | PTGER4MAPK1HSD11B1 | |
| SCHEMBL6706893 | 0.73 | MAPK1 (0.45) | MAPK1 | |
| SCHEMBL6289361 | 0.72 | MAPK1 (0.38) | MAPK1 | |
| SCHEMBL6694969 | 0.70 | MAPK1 (0.38) | MAPK1 | |
| SCHEMBL6694914 | 0.70 | MMP13 (0.39) | PTGER4 | |
| SCHEMBL6916599 | 0.67 | MMP13 (0.38) | PTGER4MAPK1 | |
| SCHEMBL6735961 | 0.67 | MMP13 (0.36) | MAPK1 | |
| SCHEMBL6471978 | 0.67 | MMP13 (0.36) | PTGER4MAPK1HSD11B1 | |
| SCHEMBL6736341 | 0.67 | MMP13 (0.39) | PTGER4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | WILSON MICHAEL WILLIAM (US) | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | MMP9, MMP1, MMP2 | PTGER4 1609/4885MAPK1 1571/4885HSD11B1 1363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.